Clinical Trials Logo

Non-squamous NSCLC clinical trials

View clinical trials related to Non-squamous NSCLC.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05751187 Recruiting - Non-squamous NSCLC Clinical Trials

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Start date: June 27, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.

NCT ID: NCT03755869 Recruiting - Non-squamous NSCLC Clinical Trials

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line(ALTER-L020)

Start date: November 29, 2018
Phase: Phase 4
Study type: Interventional

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.